DAS28 parameters at baseline and at 3-month follow-up visit for RA patients in the Swedish Rheumatology Quality Register (SRQ), 2006–2016
| Patients with complete information at 3-month follow-up visit (n=4 831) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | 3-Month follow-up visit | |||||||
| AITD+(n=530) | AITD− (n=4 301) | Mean difference Estimate(β) | 95% CI | AITD+ | AITD− | Mean difference Estimate(β) | 95% CI | |
| Patient global, mean±SD | 57.0±25.2 | 52.2±25.6 | 3.6 | 1.29 to 5.95 | 29.5±23.6 | 28.5±24.0 | 0.39 | −1.79 to 2.57 |
| ESR, mean±SD | 34.4±24.6 | 32.7±24.0 | 0.12 | −2.01 to 2.26 | 19.5±16.4 | 17.6±15.3 | 0.63 | −0.74 to 2.00 |
| SJC, mean±SD | 7.9±5.5 | 8.0±5.5 | −0.08 | −0.58 to 0.42 | 2.3±3.3 | 2.2±3.2 | 0.05 | −0.24 to 0.35 |
| TJC, mean±SD | 7.9±5.7 | 7.5±5.9 | 0.31 | −0.22 to 0.85 | 3.0±4.5 | 2.6±4.0 | 0.32 | −0.05 to 0.69 |
| DAS28, mean±SD | 5.2±1.3 | 5.1±1.3 | 0.10 | −0.02 to 0.22 | 3.3±1.3 | 3.1±1.3 | 0.07 | −0.06 to 0.19 |
| HAQ, mean±SD | 1.2±0.6 | 1.0±0.6 | 0.08 | 0.02 to 0.13 | 0.6±0.6 | 0.5±0.5 | 0.02 | −0.03 to 0.07 |
| VAS pain, mean±SD | 57.7±25.7 | 53.2±25.2 | 3.79 | 1.48 to 6.10 | 28.3±24.7 | 26.9±23.8 | 1.06 | −1.11 to 3.23 |
For each of the seven variables named in the first column and for each time point, the estimate (β) was provided by a linear regression model for which the variable in the first column was the dependent variable, AITD the independent variable, and age and sex used as adjustment. The estimate β gives the mean difference (given the linear model) between the two types of patients, a positive value meaning that the AITD+ patients have on average a higher value than the AITD− patients.
AITD, autoimmune thyroid disease; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analogue Scale.